Neuroinflammation in Dravet Syndrome Pathophysiology – Potential Therapeutic Targets
Emerging research shows that Dravet Syndrome is not solely a channelopathy but may also involve neuroinflammation. Animal models and postmortem studies indicate elevated inflammatory markers, activated microglia, and increased cytokine levels in the brains of affected individuals.
Neuroinflammation may contribute to seizure generation, neuronal injury, and cognitive decline. In turn, recurrent seizures can exacerbate inflammation, creating a vicious cycle.
Targeting neuroinflammation could open new therapeutic avenues. Anti-inflammatory drugs, immunomodulators, and therapies aimed at restoring the blood-brain barrier are under investigation. Some preclinical studies have shown that reducing inflammation can lower seizure frequency and improve behavioral outcomes, highlighting the potential of this approach.